The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
- Hurchla, M.A.
- Garcia-Gomez, A.
- Hornick, M.C.
- Ocio, E.M.
- Li, A.
- Blanco, J.F.
- Collins, L.
- Kirk, C.J.
- Piwnica-Worms, D.
- Vij, R.
- Tomasson, M.H.
- Pandiella, A.
- San Miguel, J.F.
- Garayoa, M.
- Weilbaecher, K.N.
ISSN: 0887-6924, 1476-5551
Year of publication: 2013
Volume: 27
Issue: 2
Pages: 430-440
Type: Article